Be Biopharma (Be Bio) is a private clinical-stage biotechnology company pioneering engineered B cell medicines (BCMs), a new modality that uses genetically modified B cells to deliver durable, redosable protein therapeutics. Its lead clinical program was in hemophilia B but was discontinued in June 2026 after a strategic pipeline review; the company is refocusing its platform on other genetic disease and oncology indications beyond CAR-T.
Company Info
Funding & Investor Relations
None publicly disclosed; clinical-stage cell therapy biotech with strategic platform refocus after lead program discontinuation.
Upcoming Milestones & Key Dates
Strategic update on platform refocus following lead program discontinuation
Clinical Development Pipeline
Recent News
Be Bio discontinues its lead hemophilia B cell therapy program after a clinical review, raising questions about the company's engineered B cell platform strategy and pipeline direction.
Leadership Team
Chief Executive Officer
Chief Medical Officer
Chief Scientific Officer
Careers & Job Openings